openPR Logo
Press release

Higher carcinoma lung population dominates the lung cancer therapeutics market

11-11-2019 02:27 PM CET | Health & Medicine

Press release from: CMI

Lung Cancer Therapeutics

Lung Cancer Therapeutics

Lung cancer is a malignant lung tumor, which is characterized by uncontrolled division and growth of cells in the lungs. The ability of lungs to provide oxygen into the bloodstream decreases with increasing size of tumor. The lung carcinoma is classified as, non-small cell and small cell lung cancer and originates from the epithelial cells. Lung cancer has the highest mortality rate globally, where exposure to asbestos, cigarette and pipe smoking is attributed the foremost reason. Major symptoms of lung cancer includes, body mucus, chest pain, weight loss, and coughing. Chemotherapy, immunotherapy, vaccines, and radiation therapy are the common lung cancer treatments.

According to the World Health Organization estimates in 2017, 1.8 million new lung cancer cases were diagnosed in 2012 globally accounting for the leading causes of morbidity and mortality. The launch of innovative radiation therapies, premium priced drugs, and rising incidences of non-small cell lung cancer (NSCLC) are the major driving factors for the growth of the market. The rising demand for targeted therapies is likely to have an optimistic impact over the lung cancer therapeutics market in the forecast period.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/702

Targeted therapies block the growth by targeting cancer-specific proteins, cells, and tissues that lead to cancer survival and division, without damaging the healthy cells. They are also proved to have higher efficiency over conventional therapies like platinum-based chemotherapy, surgical resection, and radiation therapy. Increasing diagnostic facilities by the Government, rise in unhealthy lifestyles, and increasing pollution due to rapid industrialization are the prominent factors driving the global lung cancer therapeutics market. The novel treatment termed targeted therapy is expected to have positive impact on the market

Regional segmentation of the lung cancer therapeutics market by Coherent Market Insights comprises North America, Europe, Asia-Pacific, Latin America and Middle East, and Africa. According to the American Cancer Society estimates of 2017, approximately 195,000 people are suffering from NSCLC every year in the U.S. where, the number of deaths from NSCLC is recorded to be around 135,000, thus increasing the demand for lung cancer therapeutics in North America.

The increasing demand in North America is also due to rising prevalence of lung cancer, increasing geriatric population, high smoking habits leading to higher carcinoma lung population. Asia Pacific is projected a higher growth rate in the forecast period owing to the growing awareness of enhanced health care, Government funding, and the presence of medical requirements for cancer therapeutics in the developing economies of India and China.

For more information, see Download PDF Copy Here @ https://www.coherentmarketinsights.com/insight/request-pdf/702

The key players operating the lung cancer therapeutics market are Pfizer, Celgene, F. Hofmann-La Roche, AstraZeneca and Eli Lilly. The key players adopt various strategies such as, development of efficient drugs, acquisition and mergers, geographical expansion and major investment in research and development to maintain their position in the market. Other prominent vendors include ARIAD Pharmaceuticals, OSE Immunotherapeutics, Novartis, Bristol-Myers Squibb, OncoGeneX.

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Higher carcinoma lung population dominates the lung cancer therapeutics market here

News-ID: 1864937 • Views: 124

More Releases from CMI

Natural And Organic Flavor Market To Reach Around US$ 10.6 Billion By 2027
CMI published a business research report on “Natural and Organic Flavors: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2018–2026”. Natural and Organic Flavors with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items. The Natural and Organic Flavors report stresses the most recent
Chocolate Market By product type, By distribution channeland By region 2027 | Ke …
CMI published a business reserch report on “Chocolate: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2018–2026”. Chocolate with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items. The Chocolate report stresses the most recent advancements, development, new chances, and lethargic traps. It gives
What is the current Trend onVideo telemedicine? Huawei technologies Co. Ltd., Po …
Video telemedicine for treating patients is important aspects of telemedicine facility, which facilitates reliable quality and clinical efficiency to in-home care, acute care and ambulatory care. Telehealth continue to gain importance in healthcare industry. Patients are realizing the value of virtual care options and substituting it for in-patient care option. Telemedicine extends the healthcare solutions to the rural patients and to the patients living in the remote location areas, which
11-11-2019 | Health & Medicine
CMI
Robust research and development activities for development of novel oral biologi …
Key players are involved in extensive research and development of novel oral biologics for various conditions In February 2019, researchers at Massachusetts Institute of Technology (MIT) developed a drug capsule with the potential to deliver an oral insulin named SOMA capsule, thereby replacing (or eliminating) the need to administer insulin via injections multiple times a day for patients with type 1 diabetes. The researchers stated that the drugs is currently under

All 5 Releases


More Releases for Lung

Non Small Cell Lung Cancer Therapeutics Market
The global non-small cell lung cancer therapeutics market is growing impressively due to recent surge in adoption of targeted therapy for treating non-small cell lung cancer. According to a report published by Fortune Business Insights, titled 'Non-Small Cell Lung Cancer Therapeutics: Global Market Analysis, Insights and Forecasts, 2019-2026,' the market value will rise substantially from US$ 16,011.7 Mn in 2018 to US$ 43,713.1 Mn by 2026. Fortune Business Insights has
Interstitial Lung Disease Therapeutics - Pipeline Analysis 2018
Interstitial lung disease is a type of inflammatory disease that affects and thickens the interstitium of the lungs. Download the sample report @ https://www.pharmaproff.com/request-sample/1126 The interstitium is a lace like network of the tissue that provide support to the air sacs and the capillaries in the interstitium which allows the gas exchange between the blood and alveolar tissues. Get the detailed analysis @ https://www.pharmaproff.com/report/interstitial-lung-disease-therapeutics-pipeline-analysis Some of the types of the condition include
Lung Cancer and Therapies Meet 2019
Lexis is the world best platform for all the researchers to showcase their on-going research work through Oral/Poster presentations in front of the international audience, provided with additional opportunities for expanding their research work by conducting workshops and by exhibiting products. It gives you the global exposure and helps to associate with the present and potential researchers who discover novel techniques to treat Lung Cancer with different approach. This meet enlightens
Acute Lung Injury Market Technological breakthroughs 2025
Acute lung injury (ALI) is commonly characterized by hypoxia, lung complication and pulmonary edema. This condition causes inflammation or direct injury to the lungs. Generally, the symptoms of this disease are divided into two forms namely, primary ALI and secondary ALI. Primary ALI is caused by the conditions like pneumonia. While, secondary ALI is mainly caused by indirect injury to the lungs. Inhalation injury, pulmonary contusions, sever trauma, shock are
Lung Cancer Treatment Market Outlook to 2022
Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions The global lung cancer drugs market was valued at $3.1bn in 2016 and is forecast to grow at a healthy 31.1% CAGR between 2016
Europe Lung Cancer Drug Pipeline Analysis
The most common type of cancer in terms of incidence and mortality rate is Lung cancer. Lung cancer is a disease in which the lining of the cell of the lung tissue has an uncontrollable growth which in turn leads to the formation of tumor. There are two main types of lung cancer; small cell lung cancer which accounts for about 20% and non-small cell lung cancer (NSCLC) that accounts